Beta-adrenergic blocking drugs, antiarrhythmic drugs, smoking reduction, and hypertension therapies are proposed as potential strategies to prevent or postpone sudden coronary death.
Does the use of beta-blockers, antiarrhythmics, smoking reduction, and hypertension therapy prevent sudden coronary death from ventricular fibrillation?
Highlights the potential of pharmacological and lifestyle interventions to prevent sudden coronary death from ventricular fibrillation in at-risk populations.
Sudden coronary death from ventricular fibrillation is the biggest and possibly the most remediable of the major public health problems at the moment. Most of those liable to sudden death can be identified and it is possible that by the use of beta-adrenergic blocking or other antiarrhythmic drugs, by reducing the consumption of cigarettes and perhaps, by different therapies for hypertension, a substantial proportion of coronary deaths might be prevented or, at least, postponed.
Desmond G. Julian (Wed,) conducted a review in Sudden coronary death from ventricular fibrillation. Beta-adrenergic blocking drugs, antiarrhythmic drugs, smoking reduction, and hypertension therapies was evaluated on Prevention of coronary death. Beta-adrenergic blocking drugs, antiarrhythmic drugs, smoking reduction, and hypertension therapies are proposed as potential strategies to prevent or postpone sudden coronary death.